Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.

Science translational medicine - 30 May 2012

Sen Banibrata, Peng Shaohua, Tang Ximing, Erickson Heidi S, Galindo Hector, Mazumdar Tuhina, Stewart David J, Wistuba Ignacio, Johnson Faye M

Abstract excerpt

During a clinical trial of the tyrosine kinase inhibitor dasatinib for advanced non-small cell lung cancer (NSCLC), one patient responded dramatically and remains cancer-free 4 years later. A comprehensive analysis of his tumor revealed a previously undescribed, kinase-inactivating BRAF mutation ((Y472C)BRAF); no inactivating BRAF mutations were found in the nonresponding tumors taken from other patients. Cells...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dasatinib

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Pyrimidines

Share to Thiazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 22649091
DOI: 10.1126/scitranslmed.3003513
PMCID: PMC3836384

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.PMID 22649091Read ↗

Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations.Semantic proximity Read ↗

Mapping the molecular determinants of BRAF oncogene dependence in human lung cancerSemantic proximity Read ↗

Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancerSemantic proximity Read ↗

The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer.Semantic proximity Read ↗

Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss.Semantic proximity Read ↗

A Braf kinase-inactive mutant induces lung adenocarcinoma.Semantic proximity Read ↗

Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts.Semantic proximity Read ↗

BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.Semantic proximity Read ↗

Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.